We provide you with 20 years of free, institutional-grade data for XTLB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of XTLB. Explore the full financial landscape of XTLB stock.
| Reported Date | CIK | Ticker | Type |
|---|
XTL Biopharmaceuticals Ltd(NASDAQ:XTLB) 
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome....
The information provided in this report about XTLB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.